CDER’s culture, its authorities, its scientific capacity, and its ability to communicate with health care providers and the public. The committee believes that the recommendations contained in this report, implemented together and with adequate resources, will enable the center (and the agency) to function more effectively in the present and to position itself for an even more challenging future in advancing and protecting the health of patients and the public.


Consumers Union. 2005. NEWS—IOM Panel Urged to Immediately Recommend that Congress Toughen Drug Safety Laws to Save Lives: Consumers Union Testifies Today That Obvious Safety Problems Need Action Now. [Online]. Available: [accessed June 9, 2005].

Grassley C. 2005. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. 109th Congress.

Harris Interactive. 2005. The Public Has Doubts About the Pharmaceutical Industry’s Willingness to Publish Safety Information About Their Drugs in a Timely Manner. [Online]. Available: [accessed March 10, 2006].

NCL (National Consumers League). 2005. Comments of the National Consumers League to DKT. No. 2005N-0394, Communication of Drug Safety Information. [Online]. Available: [accessed September 16, 2006].

PricewaterhouseCoopers’ Health Research Institute. 2005. Recapturing the Vision: Integrity Driven Performance in the Pharmaceutical Industry. [Online]. Available: [accessed February 20, 2006].

US PIRG (United States Public Interest Research Group). 2006. Drug Safety. [Online]. Available: [accessed September 16, 2006].

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement